Related Experiment Videos
Antiplatelet medications and their indications in preventing and treating coronary thrombosis
E Van De Graaff1, S R Steinhubl
1Department of Cardiology, Wilford Hall Medical Center, San Antonio, TX, USA.
Insights
New antiplatelet drugs like thienopyridines and glycoprotein IIb/IIIa inhibitors offer improved options beyond aspirin for preventing and treating coronary artery thrombosis, unstable angina, and myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Platelets are crucial in cardiovascular diseases like unstable angina and myocardial infarction.
- Aspirin was the primary antiplatelet therapy for decades.
- Newer agents offer potential improvements over aspirin.
Purpose of the Study:
- To review current antiplatelet drug classes.
- To summarize scientific data supporting their use.
- To discuss applications in cardiovascular disease management.
Main Methods:
- Review of scientific literature on antiplatelet agents.
- Analysis of clinical data for drug efficacy and safety.
- Synthesis of evidence for therapeutic applications.
Main Results:
- Three main classes of antiplatelet drugs are discussed: aspirin, thienopyridines (ticlopidine, clopidogrel), and glycoprotein IIb/IIIa inhibitors.
- These agents are used for prevention and treatment of coronary artery thrombosis.
- Evidence supports their use in unstable angina, myocardial infarction, and post-percutaneous coronary intervention.
Conclusions:
- Aspirin remains a cornerstone, but newer agents provide expanded therapeutic options.
- Thienopyridines and GP IIb/IIIa inhibitors offer enhanced strategies for managing thrombotic cardiovascular events.
- The choice of antiplatelet therapy should be guided by clinical indication and patient profile.
Abstract:
Platelets play a pivotal role in the pathophysiology of unstable angina, acute myocardial infarction, and complications following percutaneous coronary intervention. Three classes of platelet-inhibiting drugs, aspirin, thienopyridines and platelet glycoprotein IIb/ IIIa inhibitors, are now commonly used for the prevention and treatment of disorders of coronary artery thrombosis. For the last several decades aspirin has been the sole option for antiplatelet therapy in the treatment and prevention of the manifestations of cardiovascular disease. However, a wider selection of antiplatelet agents, including the thienopyridines (ticlopidine and clopidogrel) and the platelet glycoprotein (GP)IIb/IIIa receptor antagonists, are now available and provide clinicians with the opportunity to potentially improve upon the previous gold standard of aspirin. This review summarizes these drugs and the scientific data that have led to their use in primary and secondary prevention, unstable angina, myocardial infarction, and percutaneous coronary intervention.